[Impact of a new family among the therapeutic strategies: the clinician's point of view].
Poizot-Martin
I
I
Service d'Immuno-hématologie Clinique, Centre d'Informations et de Soins de l'Immunodéficience Humaine, Hôpital Sainte-Marguerite, Assistance-publique-Hôpitaux de Marseille, 270, boulevard de Sainte-Marguerite, 13009 Marseille, France.
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000639:trends; D019468:Disease Management; D004359:Drug Therapy, Combination; D005602:France; D023581:HIV Fusion Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D015337:Multicenter Studies as Topic; D017410:Practice Guidelines as Topic; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D019562:Viral Load / Q000187:drug effects; D014779:Virus Replication / Q000187:drug effects
D019380:Anti-HIV Agents; D023581:HIV Fusion Inhibitors; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors